Xarelto (rivoroxaban) is a newer generation anticoagulant/blood thinner prescribed to treat atrial fibrillation (abnormal heart rhythm) and to reduce the risk of stroke and prevent blood clots in patients following hip and knee implant surgeries.
Xarelto is a replacement drug for Coumadin (warfarin), the decades-long blood thinner treatment which requires regular monitoring of patients and may present greater risk of certain adverse reactions than does Xarelto.
The German pharmaceutical company Bayer A.G. developed Xarelto, and markets the drug through Janssen Pharmaceutical, a Belgian firm that is a division of the U.S. corporation Johnson & Johnson, which manufactures and distributes medical devices, pharmaceuticals and various consumer products.
Millions of Americans have been prescribed Xarelto since its introduction into the U.S. market in 2011.
Unfortunately, Xarelto use has been linked to uncontrollable internal bleeding and other serious side effects.